399024-19-2 (1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮,1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione)

快速询单

结构式：

1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮MOL文件

CAS号：

399024-19-2

中文名称：

1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮

英文名称：

1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione

分子式：

C₁₀H₁₃N₅O₄

分子量：

267.241321325302

1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮(399024-19-2)名称与标识符

名称

中文别名：

1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮;

英文别名：

1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione;AZT (Antiviral);AZT & Lymphoblastoid Interferon;Zidovudine (JP17/USP/INN);3'-Azido-3'-deoxythymidine & Recombinant Interferon-.alpha.-2;Intron A & AZT;1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine;Aziodothymidine;3''-Azido-3''-deoxy-thymidine;AZT & Interferon lambda-3;BSPBio_003153;MLS001055351;3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1;BBL033764;CCG-39924;Liposomal AZT-SN-3;Zidovudina [Spanish];ZIDOVUDINE [MI];Met-SDF-1.beta. & AZT;ZIDOVUDINE [AZT];3'-Azido-3'-deoxythymidine & Lithium & Granulocyte-macrophage colony-stimulating factor;5-methyl-1-[rac-(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione;KBioGR_000703;3''-azido-thymidine;399024-19-2;Zidovudine & IL-28A;AZT & CD4(178)-PE 40;3'-Azido-3'-deoxythymidine & Interleukin-6;AZT & IL-29;1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AZT);CHEMBL129;AZT & Li & EPO;SW198799-2;Thymidine, 3'-azido-3'-deoxy- & PRO 140 (Anti-CCR5 monoclonal antibody);Zidovudine & Interleukin 28A;3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6;AZT & Interferon lambda-2;Compound S;AZT & rsT4;ZIDOVUDINE [INN];Zidovudine & IL-28B;NCGC00023945-13;ZIDOVUDINE [EP MONOGRAPH];3'-Azido-3'-deoxythymidine & Interleukin-1;Timazid;DTXSID8020127;Zidovudine (Retrovir);HSDB 6515;KBio3_002653;AZT & rIFN.alpha.2;1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (N3ddThd);HMS1921J20;BWA509U;SMR000058351;AS-13019;Prestwick3_000333;NCGC00023945-03;zidovudin;Tox21_300578;NCGC00023945-09;AKOS005622576;SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle);ZIDOVUDINE [USP-RS];1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione [AZT];Spectrum2_000927;(AZT) 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;Zidovudine & IFNL1;Zidovudine & IFNL2;NCGC00023945-05;ZIDOVUDINE [JAN];ZIDOVUDINE (MART.);1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)-5-methylpyrimidine-2,4-(1H,3H)-dione;AZT & Concanavalin A (ConA);NCGC00023945-12;D88500;BW A509U;AZT & Li & GM-CSF;BDBM50002692;HMS2090G11;AZT & IL-28A;SPECTRUM1502109;3''-Deoxy-3-azidothymidine;ZIDOVUDINE COMPONENT OF TRIZIVIR;Zidovudine [USAN:USP:INN:BAN:JAN];MLS002153202;HMS2096C07;1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosy)-5-methylpyridimine-2,4-(1H,3H)-dione;1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione;BSPBio_000365;3'-Azidothymidine;3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor;NCGC00254276-01;Liposomal AZT-SN-1;Q198504;1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(azidothymidine, AZT);SR-01000000098;3'-azt;AKOS015842610;ZIDOVUDINE (USP-RS);Zidovudine & Interferon lambda-2;Antiviral AZT;BW-A 509U;NCGC00023945-06;ZIDOVUDINE [EMA EPAR];AZT & NP (from PHCA or HSA);CCRIS 105;NCGC00023945-04;AZT & IL-1;Tox21_110062;ZIDOVUDINE [IARC];KBio2_004396;Azidothymidine (AZT);AZT & Interferon lambda-1;MLS001076358;Zidovudine & Interferon lambda-1;1-((2S,4R,5R)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;1-((2R,4R,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;Thymidine, 3'-azido-3'-deoxy-;ZIDOVUDINE COMPONENT OF COMBIVIR;EN300-52518;HMS501K06;GTPL4825;Beta interferon(rIFN-beta seron) & 3'-Azido-3'-deoxythymidine(AZT);COMPOUND-S;ZIDOVUDINUM [WHO-IP LATIN];Propolis & Thymidine, 3'-azido-3'-deoxy-;HMS2234K17;ZIDOVUDINE [EP IMPURITY];K7 [P Ti2 W10 O40];Zidovudina;HMS2092D06;Met-Stromal Cell-derived Factor-1.beta. (Human) & 3'-Azido-3'-deoxythymidine;4-(4-Azido-5-hydroxy-tetrahydro-furan-2-yl)-5-methyl-3H-pyrazine-2,6-dione;NCGC00023945-24;AZT & IL-6;3'-Azido-3'deoxythymidine & Interferon .alpha.;Zidovudine & IL-29;SR-05000001587-1;4B9XT59T7S;1-((2R,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;Racemic Liposomal AZT;NCGC00014918-01;Tox21_202203;30516-87-1;Zidovudine+PRO 140;DS-4152 & AZT;ZIDOVUDINE [WHO-DD];HMS3259H17;Zidovudine, European Pharmacopoeia (EP) Reference Standard;3'-Deoxy-3'-azidothymidine;Retrovir;SR-01000000098-3;Opera_ID_1602;MLS002222249;Retrovir (TN);AZT & Interleukin 29;Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material;3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin;NCGC00178237-01;3'-Azido-3'-deoxythymidine & Concanavalin A;3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon;NSC758185;Tox21_110062_1;Azitidin;SCHEMBL14615088;AZT & SST;3'-Azido-3'-deoxythymidine, >=98% (HPLC);NINDS_000524;ZIDOVUDINE [USP MONOGRAPH];AZT & Colony-stimulating factor 2;NS00000600;ZIDOVUDINE [VANDF];SPBio_000834;1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AzddThd, AZT);3''-azido-2'',3''-dideoxythymidine;AZT & IFNL3;3-((2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)triaz-1-en-2-ium-1-ide;J-700147;ZIDOVUDINE (EP MONOGRAPH);C07210;AZT & Interleukin 28B;NC00666;Lecithinized superoxide dismutase & Thymidine, 3'-azido-3'-deoxy-;AZT, Antiviral;NSC-758185;Interferon AD + 3'-azido-3'-deoxythymidine;1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;3'-Azido-3'-deoxythymidine;AZT & rsCD4 & rIFN.alpha.A;Aztec;3'-Azido-3'-deoxythymidine, >=99.0% (HPLC);DB-225998;3'-Azido-2',3'-dideoxythymidine & sCD4(soluble recombinant protein);Zidovudine & Interleukin 29;ZIDOVUDINE [USAN];Zidovudinum;SR-05000001587;KBio2_006964;MFCD00006536;AZT & IL-2;KBio1_000524;NCGC00023945-10;Pharmakon1600-01502109;LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT ZIDOVUDINE;AZT & IFNL2;NSC 602670;Spectrum5_001101;ZIDOVUDINE [MART.];NCGC00023945-25;UNII-4B9XT59T7S;AZT & HPA;BPBio1_000403;HMS3713C07;IDI1_000524;3'-Azido-2',3'-Dideoxythymidine;3'-azido-3-deoxythimydine;Spectrum4_000332;AZT & GM-CSF;A820413;ZDV;AZT+PRO 140;AZT;zudovidine;AZT & EPO;TRIZIVIR COMPONENT ZIDOVUDINE;CHEBI:10110;ZIDOVUDINE (EP IMPURITY);BRD-K72903603-001-14-5;KBioSS_001828;AZT & Li & IL-6;AZT & IFNL1;ZIDOVUDINE [ORANGE BOOK];4lhm;Tox21_110894;AZT Antiviral;NCGC00023945-08;KBio2_001828;Cpd S;ZIDOVUDINE (USP MONOGRAPH);3' Azido 3' deoxythymidine;3'-Azido-3'-deoxythymidine & CD4-Pseudomonas exotoxin A hybrid;3''azido-2''3''-dideoxythymidine;PC-SOD+AZT;AZT & srCD4;(AZT)1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;3'-azido-3'-deoxythymidine, AZT;BW-A509U;Zidovudine (USAN:USP:INN:BAN:JAN);3' Azido 2',3' Dideoxythymidine;ZIDOVUDINE [HSDB];AZT (PHARMACEUTICAL);J05AF01;1-((2R,4S,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;AZT & IL-28B;Z754931264;Retrovir(TM);1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(AZT);BW-A-509U;zidovudine;Zidovudine & Interleukin 28B;AZT & Li & IL-1;3'azido-3'deoxythymidine;DB00495;COMBIVIR COMPONENT ZIDOVUDINE;Zidovudine & Interferon lambda-3;BRD-K72903603-001-04-6;NCGC00178237-02;AZT & IFN.alpha.;1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(Zidovudine, AZT);Azidothymidine;Zidovudinum [Latin];DTXCID60127;Spectrum_001348;SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle);Azidothymidine; Zidovudine;3'-azido3'-deoxythymidine;3'-deoxy-3'-azido-thymidine;3'-Azido-3'-deoxythymidine (AIDS);Propolis+AZT;Zidovudine, United States Pharmacopeia (USP) Reference Standard;D00413;1-((2R,4S,5S)-4-AZIDO-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE;ZIDOVUDINE [WHO-IP];1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(3''-azido-2'',3''-dideoxythymidine);3'-Azido-3'-deoxythymidine & Erythropoietin;NSC-602670;SBI-0051731.P002;Zidovudine & IFNL3;NCGC00023945-07;MLS000028548;AZT & Interferon-.alpha.-2;AZT & PM-19;AZT & Interleukin 28A;DRG-0004;STK801891;rIFN-beta seron & AZT;3'-Azido-3'-deoxythymidine & Interleukin-2;1-((2R,4S,5S)-4-azido-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;Trizivir;Met-SDF-1.beta. & Zidovudine;NCGC00259752-01;racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle);Zidovudine; 1-(3-Azido-2,3-dideoxy-?-d-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; Zidovudine (GR 63367X); BP Zidovudine and Lamivudine Impurity Standard;DivK1c_000524;Zidovudinum (Latin);S2579;3'-Azido-3'deoxythymidine & Recombinant Soluble CD4 & Recombinant Interferon.alpha.A;Spectrum3_001507;ZIDOVUDINE (IARC);3'-Azido-3'-deoxythymidine & Sho-Saiko-To;1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione;1-((2R,4S,5S)-4-(diazoamino)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;AZT & sCD4;

标识符

InChIKey：

HBOMLICNUCNMMY-XLPZGREQSA-N

Inchi：

1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

SMILES：

O1[C@H](CO)[C@H](C[C@@H]1N1C(NC(C(C)=C1)=O)=O)N=[N+]=[N-]

1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮(399024-19-2)物化性质

实验特性

LogP : log Kow = 0.05

计算特性

精确分子量 : 267.09675391g/mol
氢键供体数量 : 2
氢键受体数量 : 6
可旋转化学键数量 : 3
同位素质量 : 267.09675391g/mol
重原子数量 : 19
复杂度 : 484
同位素原子数量 : 0
确定原子立构中心数量 : 3
不确定原子立构中心数量 : 0
确定化学键立构中心数量 : 0
不确定化学键立构中心数量 : 0
共价键单元数量 : 1
疏水参数计算参考值（XlogP） : 0
拓扑分子极性表面积 : 93.2Å²

1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮(399024-19-2)相关文献

1. Impact of phosphorylation on the encapsulation of nucleoside analogues within porous iron(iii) metal–organic framework MIL-100(Fe) nanoparticles
Valentina Agostoni,Resmi Anand,Sandra Monti,Shaun Hall,Guillaume Maurin,Patricia Horcajada,Christian Serre,Kawthar Bouchemal,Ruxandra Gref J. Mater. Chem. B 2013 1 4231
2. Impact of phosphorylation on the encapsulation of nucleoside analogues within porous iron(iii) metal–organic framework MIL-100(Fe) nanoparticles
Valentina Agostoni,Resmi Anand,Sandra Monti,Shaun Hall,Guillaume Maurin,Patricia Horcajada,Christian Serre,Kawthar Bouchemal,Ruxandra Gref J. Mater. Chem. B 2013 1 4231
3. Synthesis, antioxidant and antitumoral activity of new 5′-arylchalcogenyl-3′-N-(E)-feruloyl-3′, 5′-dideoxy-amino-thymidine (AFAT) derivatives
Julliano G. Leal,Bruna Candia Piccoli,Cláudia Sirlene Oliveira,Fernanda D’Avila da Silva,Folorunsho Bright Omage,Jo?o Batista Teixeira da Rocha,Mariana Souza Sonego,Natália Vieira Segatto,Fabiana Kommling Seixas,Tiago Veiras Collares,Rafael Santos da Silva,Joelma Menegazzi Sarturi,Luciano Dornelles,Maria Amparo F. Faustino,Oscar E. D. Rodrigues New J. Chem. 2022 46 22306
4. Validated assay for the evaluation of multiple glucuronidation activities in human liver microsomes via liquid chromatography-tandem mass spectrometry
Rong Shi,Yuanyuan Yang,Jie Zhong,Tianming Wang,Yueming Ma RSC Adv. 2014 4 56132
5. Chemo-enzymatic synthesis of bicyclic 3′-azido- and 3′-amino-nucleosides
Manish Kumar,Vivek K. Sharma,Carl E. Olsen,Ashok K. Prasad RSC Adv. 2014 4 37231
6. Synthesis and configurational assignments of 3-substituted 2-deoxy-4-thio-D-erythro-pentafuranose derivatives
Houssine Ait-Sir,Nour-Eddine Fahmi,Gérard Goethals,Gino Ronco,Bougrine Tber,Pierre Villa,David F. Ewing,Grahame Mackenzie J. Chem. Soc. Perkin Trans. 1 1996 1665
7. The evolution of comprehensive strategies for furanoid glycal synthesis and their applications
Pinki Pal,Arun K. Shaw RSC Adv. 2017 7 25897
8. A quantitative analysis of Zidovudine containing formulation by FT-IR and UV spectroscopy
Ashok Peepliwal,Sagar D. Vyawahare,Chandrakant G. Bonde Anal. Methods 2010 2 1756
9. Functionalization of γ-Fe2O3@SiO2 nanoparticles using the antiviral drug zidovudine: synthesis, characterization, in vitro cytotoxicity and DNA interaction studies
Nahid Shahabadi,Monireh Falsafi,Foroozan Feizi,Reza Khodarahmi RSC Adv. 2016 6 73605
10. Preparation of a 3′-azido-3′-deoxythymidine (AZT) derivative, which is blood–brain barrier permeable
Jungkyun Im,Wanil Kim,Kyong-Tai Kim,Sung-Kee Chung Chem. Commun. 2009 4669

126543-51-9(尿苷，2’-叠氮基-2’，3’-双脱氧-5-甲基-（9CI）) 81660-73-3(异烟酸叔丁酯) 817209-46-4(辛诺林，4-氯-7-硝基-) 80904-75-2(3-(hydroxymethyl)-2H-furan-5-one) 81059-04-3(3-[(2-tert-butyl-5-methoxy-1,3-benzothiazol-6-yl)carbamothioylsulfanyl]propanoic acid) 81882-18-0(1-benzofuran-2-ylmethanamine;hydrochloride) 81720-06-1([(1aS,1bα,5aα,6aβ)-2α-(β-D-Glucopyranosyloxy)-1a,1b,2,5a,6,6a-hexahydro-1aβ-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-6α-yl]α-D-galactopyranoside) 81840-57-5(（1E）-1-（4-羟基-3-甲氧基苯基）-7-苯基庚-1-烯-3-酮)

问答

960化工网为您提供1-[(2R,4S,5S)-4-叠氮基-5-(羟基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮专业化合物百科信息，包括中文名，英文名，分子式，分子量，以及该化合物的CasNo.399024-19-2,相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等。 WAP版:399024-19-2 国际站:399024-19-2